Bank of America Starts Baxter (BAX) at Buy
More News related to BAX
- Morgan Keegan Starts BDX, HAE, BCR, MASI, COO at Outperform, BAX, HRC, COV, TFX, ISRG at Market Perform
- 2010 IR Global Rankings: Invitation for Investors and Analysts Vote for Companies with the Best IR Program and for the Best IR Officer
- Baxter (BAX) Raises Qtr Dividend 12% to $0.29/Share, 2.1% Yield
- Baxter Raises Quarterly Dividend
- New Medicare Benefit to Provide Chronic Kidney Disease Patients with Education on Treatment Options
More News related to New Coverage
- After-Hours Movers 12/01: SNTS, ABCW, RAME, GAME Higher; HEB, SWS, RGNC, LTXC Lower
- Trading Radar for 12/2: Aeropostale (ARO), Synopsys (SNPS), Shanda Interactive (SNDA), Jo-Ann Stores (JAS) Report
- Unusual 11 Mid-Day Movers 12/01: BIOF, ZN, GSIT, CAGC, RDN Higher; STAA, LTON, ZOOM, OVTI Lower
- Notable ETF Movers 12/01: FXI, EWJ, GDX, BHH Up; FXY, UUP Lower
- Notable Analyst Rating Changes 12/01: FITB, BPFH, MENT, CLWR, LTD, SPWRA Upgraded; NFLX, NUVA Downgraded
Bank of America initiates coverage on Baxter (NYSE: BAX) with a Buy rating and $60 price target.
For more analyst ratings on BAX click here.
Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
